In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scrip Team

Latest From Scrip Team

Pipeline Watch: Five Approvals And 15 Phase III Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Executives On The Move: AVEO Pharmaceuticals, Everest Medicines and More

Recent executive changes in the industry include C-suite changes at Aveo Pharmaceuticals and Scandion Oncology. Meanwhile, new directors were appointed at Akston Biosciences and Everest Medicines. 

Executive Changes Leadership

Pipeline Watch: 10 Approvals And Nine Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Executives On The Move: Beijing Konruns Pharmaceutical, KemPharm and More

Recent executive changes in the industry include C-suite changes at KemPharma and Imago BioSciences. Meanwhile, new directors were appointed at Beijing Konruns Pharmaceutical and Ventyx Biosciences. 

Executive Changes Leadership

Pipeline Watch: Five Approvals And Eight Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

The Best Of J.P. Morgan – Valuations, Deals And The IRA

Scrip reporters spoke with many biopharma industry execs and observers during the J.P. Morgan Healthcare Conference in San Francisco – here are some of the highlights from interviews and presentations. 

Business Strategies Deals
See All
UsernamePublicRestriction

Register